WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- In a new post-hoc analysis presented for the first time at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions, significantly more ...
The primary endpoint of the study was to assess if the change from baseline in HbA1c achieved with ONGLYZA 5 mg per day was non-inferior (defined in the study protocol as a treatment group numerical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback